AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 APR 18 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - A plasmid-delivered vaccine consisting of two melanoma tumor antigens enabled mice to completely overcome tumor challenge and even improved survival time for mice with established metastatic melanoma.
S.K. Mendiratta and colleagues at Valentis Inc., Woodlands, Texas, proposed that nonviral genetic vaccination enhanced with muscle electroporation could produce better results than viral delivery of melanoma self-antigens.
Vaccinating mice with plasmids encoding either human gp100 or mouse TRP-2 antigens using this delivery system only produced a partial response to challenge with B16 melanoma, reported Mendiratta and team. Using both antigens together, however, enabled all mice to reject all melanoma tumors, using splenocytes to kill syngeneic targets loaded with both gp100 and TRP-2 peptides.
The combination vaccine also improved survival time in mice with established metastatic tumors, the researchers noted ("Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2," Cancer Research, 2001;61(3):859-863).
"These results validated the usefulness of ...
Source: HighBeam Research, Nonviral, Electroporation-Assisted Vaccine Produces 100% Tumor...